VEA
IBRX icon

Virtus ETF Advisers’s ImmunityBio IBRX Stock Holding History

Virtus ETF Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-115,018
Closed -$294K – 590
2024
Q4 		$294K Buy
115,018
+58,911
+105% +$245K 0.12% 248
2024
Q3 		$209K Hold
56,107
– – 0.1% 248
2024
Q2 		$355K Buy
56,107
+34,817
+164% +$230K 0.17% 194
2024
Q1 		$114K Sell
21,290
-1,457
-6% -$6.6K 0.06% 350
2023
Q4 		$114K Sell
22,747
-11,714
-34% -$36.8K 0.07% 324
2023
Q3 		$58.2K Sell
34,461
-3,427
-9% -$6.88K 0.04% 406
2023
Q2 		$105K Buy
37,888
+22,879
+152% +$64.7K 0.06% 354
2023
Q1 		$27.3K Sell
15,009
-5,773
-28% -$17.9K 0.02% 440
2022
Q4 		$105K Sell
20,782
-14,266
-41% -$78.3K 0.06% 438
2022
Q3 		$174K Buy
35,048
+249
+0.7% +$1.14K 0.07% 332
2022
Q2 		$129K Buy
34,799
+7,456
+27% +$29.9K 0.05% 353
2022
Q1 		$153K Sell
27,343
-1,626
-6% -$9.98K 0.07% 225
2021
Q4 		$176K Buy
28,969
+14,725
+103% +$111K 0.07% 260
2021
Q3 		$139K Sell
14,244
-738
-5% -$8.12K 0.06% 354
2021
Q2 		$214K Sell
14,982
-10,868
-42% -$180K 0.09% 292
2021
Q1 		$614K Buy
25,850
+462
+2% +$12K 0.26% 120
2020
Q4 		$338K Buy
+25,388
New +$244K 0.14% 178
2016
Q4 		– Sell
-37,895
Closed -$295K – 184
2016
Q3 		$295K Hold
37,895
– – 0.14% 101
2016
Q2 		$236K Buy
37,895
+23,332
+160% +$181K 0.18% 108
2016
Q1 		$120K Buy
+14,563
New +$137K 0.17% 137

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus ETF Advisers's IBRX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 115,018 shares — an estimated $294K sold.

Virtus ETF Advisers first reported a position in IBRX in Q1 2016 and held it in 20 quarters. The position peaked at $614K in Q1 2021. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 115,018 ImmunityBio shares in Q1 2025, an estimated $294K.
  • Virtus ETF Advisers first reported a position in ImmunityBio in Q1 2016 and held it in 20 quarters.
  • Virtus ETF Advisers's ImmunityBio position peaked at $614K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.